Jeffrey Norton
Clinical Trials
- Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
- Not Recruiting Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
- Recruiting Permission to Collect Blood Over Time for Research
- Not Recruiting Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
- Not Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
- Not Recruiting Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
- Not Recruiting Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
- Not Recruiting Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample
- Not Recruiting Identification of Key Blood Molecular Markers for Immunotherapy
Help
Trial Administration